Article

Epidermal growth factor receptor expression in breast cancer association with biologic phenotype and clinical outcomes

Department of Medicine, Baylor College of Medicine, Houston, TX, USA.
Cancer (Impact Factor: 4.9). 03/2010; 116(5):1234-42. DOI: 10.1002/cncr.24816
Source: PubMed

ABSTRACT Epidermal growth factor receptor (EGFR) expression is associated with aggressive phenotypes in preclinical breast cancer models, but in clinical studies, EGFR has been inconsistently linked to poor outcome. We hypothesized that EGFR expression in human breast tumors, when centrally and uniformly assessed, is associated with an aggressive phenotype and resistance to systemic therapy.
In a database of 47,286 patients with breast cancer, EGFR status was known on 2567 tumors. EGFR levels were measured centrally by ligand binding assay, and tumors with > or =10 fmol/mg were prospectively deemed positive. Clinical and biological features of EGFR-positive and EGFR-negative tumors were compared. Clinical outcomes were assessed by systemic therapy status.
Of 2567 tumors, 475 (18%) were EGFR positive. EGFR-positive tumors were more common in younger and in black women, were larger, had a higher S-phase fraction, and were more likely to be aneuploid. EGFR-positive tumors were more likely to be HER2-positive (26% vs 16%, P < .0001), but less likely to be estrogen receptor-positive (60% vs 88%, P < .0001) or progesterone receptor-positive (26% vs 65%, P < .0001). In multivariate analyses, EGFR expression independently correlated with worse disease-free survival (hazard ratio [HR] = 1.66; 95% confidence interval [CI], 1.4-2.41, P = .007) and overall survival (HR = 1.98, 95% CI, 1.36-2.88, P = .0004) in treated patients, but not in untreated patients.
EGFR expression is more common in breast tumors in younger and black women. It is associated with lower hormone receptor levels, higher proliferation, genomic instability, and HER2 overexpression. It is correlated with higher risk of relapse in patients receiving adjuvant treatment. Blocking EGFR may improve outcome in selected patients.

Download full-text

Full-text

Available from: Mothaffar F Rimawi, Jul 31, 2015
0 Followers
 · 
72 Views
  • Source
    • "The amplification of the Her2/ neu oncogene with c-erbB2 overexpression in a subset of breast cancer patients is an example of this [2] [3] [4]. Breast cancers also overexpress the epidermal growth factor receptor (erbB1), and the presence of this growth factor receptor has been linked to a higher proliferative potential and a worsened prognosis and resistance to hormonal therapy [5]. Despite this, monotherapy inhibiting the EGF (epidermal growth factor—erbB1) receptor with erlotinib or gefitinib in unselected breast cancer patients has been disappointing , without clinical efficacy [6] [7]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: In patients with metastatic breast cancer, taxane treatment demonstrates activity but is not curative. Targeted treatment modalities are therefore necessary in order to improve outcomes in this group. A randomized placebo-controlled phase II trial was initiated to evaluate effect and toxicity of gefitinib (250 mg QD) and docetaxel 35 mg/m(2) (six of seven weeks) (NCT 00319618). The inclusion of 66 patients was planned. The study was closed due to treatment-related toxicity. Of the 18 included patients, seven (of which three received gefitinib) were withdrawn from the study due to toxicity. Of the nine patients receiving gefitinib and chemotherapy, one achieved a partial response and four stable disease. In the chemotherapy of nine patients, four had a partial response and four stable disease. The breast cancer patients in this study were genotyped using a panel of 14 single-nucleotide polymorphisms (SNPs), previously found associated with docetaxel clearance in a cohort of lung cancer patients. We were unable to identify genes related to toxicity in this study. Nevertheless, toxicity was aggravated by the addition of the tyrosine kinase inhibitor. In conclusion, despite adequately tolerated as monotherapy, combination regimens should be carefully considered for overlapping adverse events in order to avoid increased treatment-related toxicity.
    05/2012; 2012:176789. DOI:10.5402/2012/176789
  • Source
    • "The overexpression of ErbB-1 and -2 antigens in human malignancies is associated to each other and leads to heterodimer formation (Citri et al., 2004). Their expression is indirectly correlated with hormone receptor levels, and directly with higher proliferation, genomic instability and poorer overall prognosis (Rimawi et al., 2010), making ErbB- 2 expression a prognostic or possibly predictive factor (Ferretti et al., 2007). Both cetuximab and trastuzumab directly affect cellular proliferation of cancer cells: either by interfering with ligand binding (cetuximab), structure (Li et al., 2005) and heterodimerization of these membrane molecules (Patel et al., 2009), thereby inhibiting vital growth and survival signals (Lurje and Lenz, 2009); and possibly by affecting their internalization and degradation (trastuzumab) (Cuello et al., 2001; Gennari et al., 2004). "
    [Show abstract] [Hide abstract]
    ABSTRACT: To facilitate comparative oncology trials we compared the biological and molecular homologies of canine (dog; Canis lupus familiaris) and human tumor-associated antigens ErbB-1 and -2. Further, we investigated whether they could serve as targets for anti-ErbB-1 (cetuximab) and anti-ErbB-2 antibodies (trastuzumab), which are highly relevant in human clinical oncology. Immunohistochemistry of canine mammary cancer showed ErbB-1 overexpression in 3/10 patients and ErbB-2 in 4/10. We report 91% amino acid homology for ErbB-1 and 92% for ErbB-2 between canine and human molecules. Modeling of canine on human ErbB-1 revealed that the cetuximab epitope only differs by 4 amino acids: Lys443 is replaced by Arg, Ser468 by Asn, Gly471 by Asp, and Asn473 by Lys in canines. The trastuzumab binding site is identical in human and canine ErbB-2 apart from a single amino acid change (Pro557 to Ser). Binding of cetuximab and trastuzumab to canine mammary carcinoma cells CF33, CF41, Sh1b and P114 was confirmed by flow cytometry. Both antibodies significantly inhibited canine tumor cell proliferation partly due to growth arrest in G0/G1 phase. We explain the lower efficiency on the tested canine than on human SKBR3 and A431 cells, by a 2-log lower expression level of the canine ErbB-1 and -2 molecules. Our results indicate significant homology of human and canine Erb-1 and -2 tumor associated antigens. The fact that the canine homologues express the cetuximab and trastuzumab epitopes may facilitate antibody-based immunotherapy in dogs. Importantly, the striking similarities of ErbB-1 and -2 molecules open up avenues towards comparative strategies for targeted drug development.
    Molecular Immunology 04/2012; 50(4):200-9. DOI:10.1016/j.molimm.2012.01.002 · 3.00 Impact Factor
  • Source
    • ") . Loss of PR in ER + tumors is associated with overexpression of EGFR and HER2 ( Bamberger et al . , 1996 ; Dixon et al . , 2004 ; Rimawi et al . , 2010 ; Taucher et al . , 2003 ) , and upregulation of the PI3K / Akt / mTOR sig - naling pathway ( Creighton et al . , 2009 ; Tokunaga et al . , 2006a , b ) . Mammary tumors in transgenic mice overexpressing the coactiva - tor AIB1 have elevated ER , loss of PR , and increased IGF - I activation of the PI3K / Akt / mTOR pathway ( Torres - Ar"
    [Show abstract] [Hide abstract]
    ABSTRACT: This paper reviews work on progesterone and the progesterone receptor (PR) in the mouse mammary gland that has been used extensively as an experimental model. Studies have led to the concept that progesterone controls proliferation and morphogenesis of the luminal epithelium in a tightly orchestrated manner at distinct stages of development by paracrine signaling pathways, including receptor activator of nuclear factor κB ligand (RANKL) as a major paracrine factor. Progesterone also drives expansion of stem cells by paracrine signals to generate progenitors required for alveologenesis. During mid-to-late pregnancy, progesterone has another role to suppress secretory activation until parturition mediated in part by crosstalk between PR and prolactin/Stat5 signaling to inhibit induction of milk protein gene expression, and by inhibiting tight junction closure. In models of hormone-dependent mouse mammary tumors, the progesterone/PR signaling axis enhances pre-neoplastic progression by a switch from a paracrine to an autocrine mode of proliferation and dysregulation of the RANKL signaling pathway. Limited experiments with normal human breast show that progesterone/PR signaling also stimulates epithelial cell proliferation by a paracrine mechanism; however, the signaling pathways and whether RANKL is a major mediator remains unknown. Work with human breast cancer cell lines, patient tumor samples and clinical studies indicates that progesterone is a risk factor for breast cancer and that alteration in progesterone/PR signaling pathways contributes to early stage human breast cancer progression. However, loss of PR expression in primary tumors is associated with a less differentiated more invasive phenotype and worse prognosis, suggesting that PR may limit later stages of tumor progression.
    Molecular and Cellular Endocrinology 12/2011; 357(1-2):4-17. DOI:10.1016/j.mce.2011.10.030 · 4.24 Impact Factor
Show more